CD44 and melanoma: In addition, soon after the identification of a pro-metastatic role for the CD44 variants, it was demonstrated that a monoclonal antibody against CD44 was able to completely inhibit the binding of human melanoma cells to extracellular hyaluronate in vitro and to inhibit metastases of melanoma cells in vivo [21].